...Inc. (NASDAQ:VRTX) bought in 2009 for $413.1 million in cash and stock; and cancer company Gemin X Pharmaceuticals Inc....

...million. Therillia will be run by the management team of Sanderling's former Canadian portfolio company Gemin X Pharmaceuticals Inc....
...lower in Canada than the U.S.," noted Therillia CEO Michael Dixon, who was CFO at Gemin X...

...Mass. Business: Musculoskeletal Hired: Arthur Fratamico as CBO, a newly created position, formerly CBO of Gemin X Pharmaceuticals Inc....

...company sales to Cephalon Inc. (now part of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). Cephalon bought Gemin X Pharmaceuticals Inc....

...had several exits over the last six years, including last year's sale of cancer company Gemin X Pharmaceuticals Inc....

...APO866 , which is in Phase II testing to treat cutaneous T cell lymphoma (CTCL). Gemin X Pharmaceuticals Inc....

...performance status of 0 or 1 in 1Q12. Cephalon gained obatoclax through its acquisition of Gemin X Pharmaceuticals Inc....

...antagonist of B cell lymphoma 2 ( BCL-2 ; BCL2 ) through its acquisition of Gemin X Pharmaceuticals Inc....

...of Prussia, Pa. Business: Cardiovascular, Neurology, Autoimmune Hired: Arthur Fratamico as CBO, formerly CBO of Gemin X Pharmaceuticals Inc....

...has announced six acquisitions since the beginning of 2009, including proposals to buy cancer plays Gemin X Pharmaceuticals Inc....
...in the B cell lymphoma 2 ( BCL2 ) family. The company proposed to acquire Gemin X...
...inhibitor from ChemGenex; and teglarinad, a prodrug of a nicotinamide phosphoribosyl transferase (NamPRT) inhibitor from Gemin X...